Seaport Therapeutics, Inc.

Seaport Therapeutics, Inc. 3 Ağustos 2026 tarihinde ne bildirdi

Şirketin kendi 8-K belgesinden.

Kazanç çağrıları

Seaport Therapeutics, Inc. için kazanç çağrısı dökümü mevcut değil.

Yönetim ne dedi

“The second quarter of 2026 was marked by two major milestones for Seaport – positive results from our Phase 1 proof-of-concept trial of GlyphAgo and the successful completion of our IPO,”

Açıklamadan birebir alıntılanmıştır ve yalnızca belge sözü adı geçen bir kişiye atfettiğinde gösterilir.

Fiyat nasıl tepki verdi

Açıklamalar kapanıştan sonra ya da açılıştan önce gelir, dolayısıyla hareket bir sonraki seansa aittir.

Seaport Therapeutics, Inc. ne yapar

Seaport Therapeutics (Nasdaq: SPTX) is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Through its differentiated approach, the Company identifies clinically validated mechanisms with established efficacy and safety which had historically been limited by high first-pass metabolism, low bioavailability, and/or side effects. Seaport applies its proprietary Glyph TM platform to overcome those limitations and invent innovative oral therapies. With an experienced team of industry leaders, Seaport has a proven track record in neuropsychiatry drug discovery and development and delivering successful business outcomes. Seaport aims to develop novel, leading treatment options that will make a significant impact for patients and their families.

Şirketin kendi tanımı, açıklamanın sonunda göründüğü hâliyle.